News - Page 49 of 72 - Yokohama City University

2021-07-27

Clinical evidence that a dysregulated master neural network modulator mayaid in diagnosing schizophrenia

Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients.

2021-07-20

Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease

The transcription factor IRF5 has been implicated as a therapeutic target for the autoimmune disease systemic lupus erythematosus (SLE). However, IRF5 activation status during the disease course and the effects of IRF5 inhibition after disease onset are unclear.

2021-07-05

The N-terminal Tails of Histones H2A and H2B Adopt Two Distinct Conformations in the Nucleosome with Contact and Reduced Contact to DNA

Antibody labeling has been conducted extensively for structure determination using both X-ray crystallography and electron microscopy (EM). However, establishing target-specific antibodies is a prerequisite for applying antibody-assisted structural analysis. To expand the applicability of this strategy, an alternative method has been developed to prepare an antibody complex by inserting an exogenous epitope into the target.

2021-07-01

Online PBL Session with the University of Hawaii John A. Burns School of Medicine

The YCU School of Medicine always sees the importance of offering our students world-standard medical education. As a part of our efforts, we have sent more than 10 faculty members in past years to the “PBL* Hawaii Style Workshop” organized by the University of Hawaii John A. Burns School of Medicine (JABSOM),